Dornase alfa for cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 4, 2016, Pages

  Yang, Connie ^a   Chilvers, Mark ^a   Montgomery, Mark ^b   Nolan, Sarah J ^c  

^a BC CHILDREN S HOSPITAL   (Canada)

^b ALBERTA CHILDREN'S HOSPITAL   (Canada)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DNA; DORNASE ALFA; PLACEBO; SODIUM CHLORIDE; DEOXYRIBONUCLEASE I; EXPECTORANT AGENT; MANNITOL; RECOMBINANT PROTEIN;

COMPARATIVE STUDY; DISEASE EXACERBATION; DRUG COST; DYSPNEA; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEMOPTYSIS; HUMAN; HYPEROSMOLARITY; LIFE EXPECTANCY; LUNG CLEARANCE; LUNG FIBROSIS; LUNG FUNCTION; META ANALYSIS; MORBIDITY; MORTALITY; NEUTROPHIL; OUTCOME ASSESSMENT; PNEUMOTHORAX; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESPIRATORY FAILURE; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; VOICE CHANGE; ADOLESCENT; CHILD; CYSTIC FIBROSIS; INFANT; PRESCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; EXPECTORANTS; HUMANS; INFANT; MANNITOL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; SALINE SOLUTION, HYPERTONIC;

EID: 84962660366     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001127.pub3     Document Type: Review

References (133)

1. Adde FV, Borges KTL, Hatanaka ACF, Nakaie CMA, Cardieri JMA, Oliveira RC, et al. Hypertonic saline X recombinant human DNase: a randomised cross-over study in 18 cystic fibrosis patients [abstract]. Journal of Cystic Fibrosis 2004;3(Suppl 1):S66.
2. Amin R, Subbarao P, Lou W, Jabar A, Balkovec S, Jensen R, et al. The effect of dornase alfa on ventilation in homogeneity in patients with cystic fibrosis. European Respiratory Journal 2011;37(4):806-12. [CFGD Register: BD163b]
3. Amin R, Subbarao P, Lou W, Jabar A, Balkovec S, Jensen R, et al. The effect of dornase alfa on ventilation in homogeneity in patients with cystic fibrosis [abstract]. Pediatric Pulmonology 2010;45(Suppl 33):361, Abstract no: 396. [CFGD Register: BD163a]
4. Ballmann M, von der Hardt H. Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis 2002;1(1):35-7.
5. Ballmann M, von der Hardt H. Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:80.
6. Castile R, Mueller G, Long F, Flucke R, Baker B, Clifford B. Effects of nebulized recombinant human deoxyribonuclease (dornase alfa) in infants with CF evaluated using infant pulmonary function testing and high resolution computerized tomographic imaging of the chest [abstract]. Pediatric Pulmonology 2009;32(Suppl 32):357, Abstract no: 414. [CFGD Register: BD161a]
7. NCT00179998 Efficacy of Pulmozyme in infants and young children with cystic fibrosis. http://clinicaltrials.gov/show/NCT00179998 2005. [CFGD Register: BD161b; CRS: 5500100000011130]
8. Dodd ME, Moorcroft AJ, Haworth CS, Francis S, Miles, J, Clayton N, et al. The effect of rhDNase on exercise performance and gas trapping in adults with cystic fibrosis: a randomised controlled trial [abstract]. Proceedings of the 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm. 2000:147.
9. Frederiksen B, Koch C, Hoiby N, Pressler T, Hansen A. Effect of aerosolised or rhDNase (Pulmozyme®) on pulmonary infections in CF: an open randomised study (abstract). Pediatric Pulmonology 2000;Suppl 20:246.
10. Frederiksen B, Pressler T, Hansen A, Koch C, Hoiby N. Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatrica 2006;65(9):1070-4.
11. Eisenberg J. Clinical development of rhDNase in the United States [Developpement clinique de la rhDNase aux Etats-Unis]. Archives de Pediatrie 1995;2(7):674-8.
12. Fuchs HJ, Borowitz D, Christiansen D, Morris E, Nash M, Ramsey B, et al. Aerosolised recombinant human DNase reduces pulmonary exacerbations and improves pulmonary function in patients with cystic fibrosis [abstract]. Proceedings of the 36th Annual Conference on Chest Disease; 1993. 1993.
13. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. New England Journal of Medicine 1994;331(10):637-42.
14. Menzin J, Oster G, Davies L, Drummond MF, Greiner W, Lucioni C, et al. A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis. International Journal of Technology Assessment in Healthcare 1996;12(1):52-61.
15. Oster G, Huse D, Lacey MJ, Regan MM, Fuchs HJ. Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis. Annals of Pharmacotherapy 1995;29(5):459-64.
16. Ramsey B for the Pulmozyme (rhDNase) Study Group. A summary of the results of the phase III multicenter clinical trial: aerosol administration of recombinant human DNase reduces the risk of respiratory tract infections and improves pulmonary function in patients with cystic fibrosis [abstract]. Pediatric Pulmonology 1993;Suppl 9:152-3.
17. von der Schulenburg JMG, Greiner W, von der Hardt H. Socioeconomic evaluation of the influence of rhDNase on the costs of treating respiratory tract infections in patients with cystic fibrosis [Sozioökonomische Evaluation des Einflusses von rhDNase auf die Kosten der Behandlung von Infektionen der Atemwege bei Patienten mit zysticher fibrose]. Medizinische Klinik 1995;90(4):220-4.
18. Laube BL, Auci RM, Shield DE, Christiansen DH, Lucas MK, Fuchs HJ, et al. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 1996;153(2):752-60.
19. Laube BL, Auci RM, Shields DE, Christiansen D, Fuchs HJ, Rosenstein BJ. A randomized, placebo-controlled trial of the effect of recombinant human DNase (rhDNase) on the deposition homogeneity and mucociliary clearance of radioaerosol in patients with cystic fibrosis [abstract]. Pediatric Pulmonology 1993;Suppl 9:155-6.
20. McCoy K for the Pulmozyme Severe Lung Disease Study Group. rhDNase is well tolerated and effective in cystic fibrosis patients with severe obstructive ling disease [abstract]. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18-21; Brussels, Belgium. 1995:L41.
21. McCoy K, Hamilton S, Johnson CAC, for the Pulmozyme study group. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Chest 1996;110(4):889-95.
22. Minasian C, Wallis C, Metcalfe C, Bush A. Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial. Thorax 2010;65(1):51-6. [CFGD Register: BD133b]
23. Minasian CC, Wallis C, Metcalfe C, Bush A. A crossover comparative study of inhaled mannitol, alone and in combination with daily rhDNase, in children with cystic fibrosis [abstract]. Pediatric Pulmonology 2008;43(Suppl 31):301. [CFGD Register: BD133a]
24. Griese M, Essl R, Schmidt R, Ballmann M, Paul K, Rietschel E, et al. Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients. Respiratory Research 2005;6:133.
25. Jung A, Shute JK, Chen CIU, Ballmann M, Griese M, Ratjen F, et al. Influence of long-term inhaled rhDNase on free and total IL-8 concentration in BAL fluid in cystic fibrosis [abstract]. Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sep 14-18; Stockholm. 2002:P3285.
26. Paul K, Ballmann M, Griese M, Rietschel E, Chen C, Schink T, et al. Effect of rhDNase on endobronchial inflammation in CF patients with mild lung disease: results of multi-center beat study [abstract]. Pediatric Pulmonology 2002;Suppl 24:310-11.
27. Paul K, Rietschel E, Ballmann M, Griese M, Worlitzsch D, Shute J, et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2004;169(6):719-25.
28. Paul KP, Ballmann M, Dorig G, Griese M, Kleinau I, Ratjen F, et al. Airway inflammation in CF patients with good pulmonary function - baseline data from the multicenter "Beat" study [abstract]. Pediatric Pulmonology 1998;Suppl 17:383-4.
29. Paul KP, Rietschel E, Ballmann M, Griese M, Chen CI, Schink T, et al. Longitudinal Evaluation of Airway Inflammation in Stable Cystic Fibrosis (CF) Patients by Bronchoalveolar Lavage (BAL) and Influence rhDNase [abstract]. American Thoracic Society International Conference; 2003 May 16-21; Seattle, USA.. 2003:Poster E42.
30. Ratjen F, Griese M, Ballmann M, Rietschel E, Paul K, Beat Study Group. Dornase alpha in pediatric CF patients with normal lung function - effects on airway inflammation [abstract]. Pediatric Pulmonology 2005;40(Suppl 28):143.
31. Ratjen F, Paul K, Rietschel E, Nikolaizik W. Treatment with rhDNase reduces DNA levels in BAL fluid of CF patients with mild lung disease [abstract]. Pediatric Pulmonology 2002;Suppl 24:310.
32. Ratjen F, Paul K, van Koningsbruggen S, Breitenstein S, Rietschel E, Nikolaizik W. DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: Influence of treatment with dornase alpha. Pediatric Pulmonology 2005;39(1):1-4.
33. Brody A, Molina PL, Klein JS, Campbell JD, Millard SP, Quan J. High-resolution CT is more sensitive to longitudinal decline in lung status in young children with CF than pulmonary function tests [abstract]. Pediatric Pulmonology 2003;Suppl 25:318.
34. Grasemann H, Lax H, Treseler JW, Colin AA. Dornase alpha and exhaled NO in cystic fibrosis. Pediatric Pulmonology 2004;38(5):379-85.
35. Konstan MW, Wohl ME, McKenzie S, Sy J, Quan JM, Tiddens HA. A randomized, placebo-controlled trial of two years' treatment with dornase alfa (Pulmozyme®) in cystic fibrosis patients aged 6-10 years with early lung disease [abstract]. Pediatric Pulmonology 2000;Suppl 20:299-300.
36. Quan JM, Tiddens HAWM, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, et al. A two-year randomized, placebo controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. Journal of Pediatrics 2001;139(6):813-20.
37. Robinson PJ. Dornase alfa in early cystic fibrosis lung disease. Pediatric Pulmonology 2002;34(3):237-41.
38. Ramsey BW, Astley SJ, Aitken ML, Burke W, Colin AA, Dorkin HL, et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. American Review of Respiratory Disease 1993;148(1):145-51.
39. Ranasinha C, Assoufi B, Shak S, Christiansen D, Fuchs HJ, Empey D, et al. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet 1993;342(8865):199-202.
40. Ranasinha C, Empey D, Geddes D, Fuchs H, Hodson ME. A phase 2 double-blind placebo controlled study of the pulmonary function and the safety of aerosolised recombinant human DNase in adults with stable stage cystic fibrosis [abstract]. Proceedings of the 11th International Cystic Fibrosis Congress; 1992. 1992:LBS5.
41. Shah PL, Scott SF, Knight RA, Marriott C, Ransinha C, Hodson ME. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis. Thorax 1996;51(2):119-25.
42. Hemming AL, Robinson M, Moriarty C, Bautovich GJ, Bye PTP. Effect of short course of rhDNase on mucociliary clearance in patients with cystic fibrosis [abstract]. Pediatric Pulmonology 1997;Suppl 14:273.
43. Robinson M, Hemming AL, Moriarty B, Eberl S, Bye PTP. Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis. Pediatric Pulmonology 2000;30(1):16-24. [CFGD Register: BD76b]
44. Robinson T, Leung AN, Northway WH, Blankenberg FG, Chan F, Bloch DA, et al. Composite CT/PFT score: an outcome measure which markedly improves sensitivity to change in early cystic fibrosis lung disease [abstract]. Pediatric Pulmonology 2002;Suppl 24:298. [CFGD Register: BD106a]
45. Robinson TE, Goris ML, Zhu HJ, Chen X, Bhise P, Sheikh F, et al. Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis. Chest 2005;128(4):2327-35. [CFGD Register: BD106c]
46. Robinson TE, Leung AN, Northway WH, Blankenberg FG, Chan FP, Bloch DA, et al. Composite spirometric-computed tomography outcome measure in early cystic fibrosis lung disease. American Journal of Respiratory and Critical Care Medicine 2003;168(5):588-93. [CFGD Register: BD106b]
47. Hodson M. Multicenter study of rhDNase in cystic fibrosis with severe pulmonary involvement [Étude multicentrique de la rhDNase dans les mucoviscidoses avec atteinte pulmonaire grave]. Archives de Pediatrie 1995;2(7):679-81. [CFGD Register: BD42c]
48. Shah PI, Bush A, Canny GJ, Colin AA, Fuchs HJ, Geddes DM, et al. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment. European Respiratory Journal 1995;8(6):954-8. [CFGD Register: BD42b]
49. Shah PL, Dewar A, Hodson ME. Scanning electron microscopy of cystic fibrosis sputum [abstract]. European Respiratory Journal 1995;8(Suppl 19):574S. [CFGD Register: BD38e]
50. Shah PL, Scott SF, Hodson ME (on behalf of the multicentre study group). Report on a multicentre study using aerosolised recombinant human DNase I in the treatment of cystic fibrosis patients with severe pulmonary disease [abstract]. Pediatric Pulmonology 1993;Suppl 9:157-8. [CFGD Register: BD42a]
51. Shah PL, Scott SF, Knight RA, Marriott C, Hodson ME. The effects of recombinant human DNase I on sputum DNA content [abstract]. European Respiratory Journal 1995;8(Suppl 19):574S. [CFGD Register: BD38d]
52. Grieve R, Thompson S, Normand C, Suri R, Bush A, Wallis C. A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care 2003;19(1):71-9.
53. Suri R, Grieve R, Normand C, Metcalfe C, Thompson S, Wallis C, et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax 2002;57(10):841-6.
54. Suri R, Grieve R, Normand C, Metcalfe C, Thompson S, Wallis C, et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis [abstract]. Thorax 2001;56(Suppl 3):iii84.
55. Suri R, Marshall LJ, Wallis C, Metcalfe C, Bush A, Shute JK. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2002;166(3):352-5.
56. Suri R, Marshall LJ, Wallis C, Metcalfe C, Thompson S, Bush A, et al. Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology 2001;Suppl 22:281.
57. Suri R, Metcalfe C, Lees B, Flather M, Normand C, Thompson S, et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis [abstract]. Thorax 2000;55:A75.
58. Suri R, Metcalfe C, Lees B, Grieve R, Flather M, Normand C, et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001;358(9290):1316-21.
59. Suri R, Metcalfe C, Wallis C, Bush A. Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine 2007;101(2):254-60.
60. Suri R, Metcalfe C, Wallis C, Bush A. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis. Pediatric Pulmonology 2004;37:305-10.
61. Suri R, Wallis C, Bush A. In vivo use of hypertonic saline in CF [abstract]. Pediatric Pulmonology 2000;Suppl 20:125-6.
62. Suri R, Wallis C, Bush A, Thompson S, Normand C, Flather M, et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment (HMSO) 2002; Vol. 6, issue No.34.
63. Wilmott R and the DNase Multicenter Study Group and Genentech staff. A phase II, double blind, multicenter study of the safety and efficacy of aerosolized recombinant human DNase I in hospitalized patients with CF experiencing acute pulmonary exacerbations [abstract]. Pediatric Pulmonology 1993;Suppl 9:154.
64. Wilmott RW, Amin RS, Colin AA, De Vault A, Dozor AJ, Eigen H, et al. Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations. American Journal of Respiratory and Critical Care Medicine 1996;153(6 Pt 1):1914-7.
65. Anderson P, Morton J. Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with cystic fibrosis [abstract]. Journal of Cystic Fibrosis 2009;8 Suppl 2:S74, Abstract no: 299. [CFGD Register: BD162]
66. Bakker EM, Volpi S, Salonini E, Mullinger B, Kroneberg P, Hop WCJ, et al. Efficacy of peripheral deposition of inhaled rhDNase in CF patients during a respiratory tract infection [abstract]. Journal of Cystic Fibrosis 2010;9 Supplement 1:S62, Abstract no: 239. [CFGD Register: BD155a]
67. Bakker M, Volpi S, Salonini E, van der Wiel E, Merkus P, Sintnicolaas C, et al. Peripheral versus central deposition of inhaled rhdnase in children with cystic fibrosis [abstract]. Pediatric Pulmonology 2010;45(S33):306, Abstract no: 244. [CFGD Register: BD155b]
68. van den Beukel-Bakker M, Volpi S, Salonini E, van der Wiel-Kooij EC, Sintnicolaas C, Hop WC, et al. Small airways response to dornase alfa improves using controlled inhalation: a randomized controlled trial in cystic fibrosis patients [abstract]. Journal of Cystic Fibrosis 2011;10 Supplement 1:S19, Abstract no: 75. [CFGD Register: BD155c]
69. Bollert FG, Paton JY, Marshall TG, Calvert J, Greening AP, Innes JA. Recombinant DNase in cystic fibrosis: a protocol for targeted introduction through n-of-1 trials. Scottish Cystic Fibrosis Group.. European Respiratory Journal 1999;13(1):107-13.
70. Bollert FGE, McArthur DA, Greening AP, Innes JA on behalf of the Scottish Cystic Fibrosis Group. Targeted introduction of DNase in Scotland [abstract]. Pediatric Pulmonology 1995;Suppl 12:204.
71. Cimmino M, Nardone M, Cavaliere M, Plantulli A, Sepe A, Esposito V, et al. Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease. Archives of Otolaryngology - Head and Neck Surgery 2005;131(12):1097-101.
72. Craig T. Pulmozyme in cystic fibrosis with sinusitis. clinicaltrials.gov/ct2/show/NCT01155752 (accessed 14 April 2015).
73. Dab A, Malfroot D, Baran EM, App M, Coffiner M, Nagy AM. Randomized multicentric double blind study of safety and efficacy of Nacystelyn DPI versus placebo in rhDNase treated cystic fibrosis patients [abstract]. American Journal of Respiratory and Critical Care Medicine 2000;161(3):A72.
74. Malfroot A, Dab I, Baran D, App EM, Coffiner M, Nagy AM. Randomised multicentric double blind study of tolerability and efficacy of a DPI Nacystelyn versus placebo in cystic fibrosis patients treated by rhDNase for at least 3 months [abstract]. Proceedings of the 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden. 2000:146.
75. Malfroot A, Dab I, Baran D, App EM, Coffiner M, Nagy AM. Randomized multicentric double blind study of tolerability and efficacy of a DPI Nacystelyn versus placebo in cystic fibrosis patients treated by rhDNase for at least 3 months [abstract]. Pediatric Pulmonology 1999;Suppl 19:244.
76. Diot P. RhDNase and Biodistribution of PMN Serine Proteases in Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00843817 accessed April 15, 2015.
77. Elkins MR, Bye PTP. Comparison of Pari LC-Star and -Plus nebulisers delivering 2.5mg recombinant human deoxyribonuclease (rhDNase) [abstract]. Journal of Cystic Fibrosis 2006;5 Suppl:S42.
78. Fitzgerald DA, Hilton J, Jepson B, Smith L. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics 2005;116(4):e549-54.
79. Fitzgerald DA, Hilton J, Smith L, Jepson B. Is dornase alfa (pulmozyme) more effective before or after physiotherapy? A cross-over, randomised placebo controlled trial [abstract]. Pediatric Pulmonology 2001;Suppl 22:309-10.
80. Middleton PG, Bishop J. Dornase alpha and physiotherapy - which should be first? A randomised double-blind, placebo-controlled trial in CF adults [abstract]. Pediatric Pulmonology 2001;Suppl 22:310.
81. Genentech Inc. A study of Pulmozyme® (dornase alpha) in 3- to 5-year-old patients with cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00680316 (accessed 14 April 2015). [clinicaltrials.gov: NCT00680316]
82. Furuya ME, Lezana-Fernandez JL, Vargas MH, Hernandez-Sierra JF, Ramirez-Figueroa JL. Efficacy of human recombinant DNase in pediatric patients with cystic fibrosis. Archives of Medical Research 2001;32(1):30-4.
83. Genentech Inc. A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects with Severe Lung Disease (TOPIC). https://clinicaltrials.gov/ct2/show/results/NCT00434278 accessed April 15, 2015.
84. Griese M, App EM, Derouix A, Burkert A, Schams A. Recombinant human DNase (rhDNase) influences phospholipid composition, surface activity, rheology and consecutively clearance indices of cystic fibrosis sputum. Pulmonary Pharmacology and Therapeutics 1997;10(1):21-7.
85. Hagelberg M, Dooley MJ, Poole SG, Leung D, Bailey M, Finlayson F, et al. Direct dispensing of dornase alpha improves adherence and lung function in cystic fibrosis [abstract]. Journal of Cystic Fibrosis 2008;7(Suppl 2):S27.
86. Heijerman HGM, van Rossem RN, Bakker W. Effect of rhDNase on lung function and quality of life in adult cystic fibrosis patients. The Netherlands Journal of Medicine 1995;46(6):293-7.
87. Hubbard RC, McElvaney NG, Birrer P, Shak S, Robinson WW, Jolley C, et al. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. New England Journal of Medicine 1992;326(12):812-5.
88. Johnson JC, Waldrep JC, Dhand R. Aerosol delivery of recombinant human DNase 1. Comparison of a vibrating mesh nebulizer with a jet nebulizer [abstract]. American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A82.
89. King M, Dasgupta B, Tomkiewicz RP, Brown NE, Pulmonary Research Group. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. American Journal of Respiratory and Critical Care Medicine 1997;156(1):173-7.
90. Lahiri T. Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00416182?term=nct00416182&rank=1 accessed 14 April 2015.
91. Laube BL, Geller DE, Lin TC, Dalby RN, Diener-West M, Zeitlin PL. Positive expiratory pressure changes aerosol distribution in patients with cystic fibrosis. Respiratory Care 2005;50(11):1438-44.
92. Laube BL, Lin T, Geller D, Dalby R, Zeitlin P. Positive expiratory pressure alters aerosol distribution in CF [abstract]. Pediatric Pulmonology 2000;Suppl 20:247.
93. Mainz J, Mentzel H, Scheider G, Riethmuller J, Schiller I, Ritschel C, et al. Double-blind, placebo-controlled pilot trial on sinonasal inhalation of dornase alfa in CF [abstract]. Pediatric Pulmonology 2008;43(Suppl 31):305.
94. Mainz J, Mentzel HJ, Schneider G, Riethmuller J, Schiller I, Ritschel C, et al. Sinu-nasal inhalation of Dornase alfa in CF. Results of a double-blind placebo-controlled pilot trial [abstract]. Journal of Cystic Fibrosis 2008;7(Suppl 2):S27.
95. Mainz JG, Schiller I, Koitschev A, Koitschev C, Riethmuller J, Wiedemann B, et al. Sinonasal inhalation of dornase alfa reduces rhinosinusitis symptoms in CF. Results of a DBPC-cross-over-study [abstract]. Journal of Cystic Fibrosis 2010;9(Suppl 1):S23, Abstract no: 88. [CFGD Register: BD154]
96. Majaesic CM, Montgomery M, Jones R, King M, et al. Reduction in sputum viscosity using high frequency chest compressions (HFCC) compared to conventional chest physiotherapy (CCP) [abstract]. Pediatric Pulmonology 1996;Suppl 13:308.
97. Nasr SZ, Kuhns LR, Brown RW, Hurwitz ME, Sanders GM, Strouse PJ. Use of computerized tomography and chest-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than 5 years: A preliminary study. Pediatric Pulmology 2001;31(5):377-82.
98. Nasr SZ, Kuhns LR, Brown RW, Hurwitz RW, Sanders GM, Stouse PJ. Aerolized recombinant human DNase in cystic fibrosis patients younger than 5 years of age [abstract]. Pediatric Pulmonology 1999;Suppl 19:278.
99. Potter RW, Hurren TJ, Nickerson C, Hatley RH. Comparison of the delivery characteristics of Dornase alfa from the I-NEB AAD system and the sidestream jet nebulizer [abstract]. Pediatric Pulmonology 2008;43(Suppl 31):361.
100. Riethmueller J, Borth-Bruhns T, Kumpf M, Vonthein R, Wiskirchen J, Stern M, et al. Recombinant human deoxyribonuclease shortens ventilation time in young, mechanically ventilated children. Pediatric Pulmonology 2006;41(1):61-6.
101. Robinson T, Goris ML, Bhise P, Sathi A, Zhu JH, Moss RB. Quantitative HRCT air trapping analysis in CF subjects with mild lung disease during a pulmozyme intervention study [abstract]. Pediatric Pulmonology 2002;Suppl 24:298. [MU 94]
102. Konstan MW, Chou W, Trzaskoma B, Xu Y. A study to evaluate the comparable efficacy and safety of Pulmozyme® delivered by the Erapid™ nebulizer system [abstract]. Pediatric Pulmonology 2013;48 Suppl 36:452, Abstract no: 668. [CENTRAL: 999883; CFGD Register: BD219c; CRS: 5500127000000005]
103. Sawicki GS, Chou W, Raimundo K, Trzaskoma B, Konstan MW. Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients. Journal of Cystic Fibrosis 2015;14(6):777-83. [CFGD Register: BD219d]
104. Sawicki GS, Konstan M, Chou W, Trzaskoma B, Raimundo K. Impact of dornase alfa delivered by the eRapid™ vs. Pari LC® plus jet nebulizer system on cystic fibrosis-related quality of life - results from the IMPART Study [abstract]. Pediatric Pulmonology 2014;49 Suppl 38:445-446, Abstract no: 621. [CENTRAL: 1012526; CFGD Register: BD219a; CRS: 5500131000000180]
105. Sawicki GS, Konston M, Chou W, Trzaskoma B, Raimundo K. Treatment preferences and satisfaction with dornase alfa delivered by the eRapid™ vs. Pari LC® plus jet nebulizer system to patients with cystic fibrosis - results from the IMPART Study [abstract]. Pediatric Pulmonology 2014;49 Suppl 38:444, Abstract no: 617. [CENTRAL: 1012527; CFGD Register: BD219b; CRS: 5500131000000182]
106. Shah PL, Scott SF, Geddes DM, Hodson ME. Two years of experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respiratory Medicine 1995;89(7):499-502. [CFGD Register: BD132]
107. Shah PL, Scott SF, Fuchs HJ, Geddes DM, Hodson ME. Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I. Thorax 1995;50(4):333-8. [CFGD Register: BD127]
108. Shah PL, Scott SF, Geddes DM, Conway S, Carr S, Wallis C, et al. An evaluation of two aerosol delivery systems for rhDNase [abstract]. Israel Journal of Medical Sciences 1996;32(Suppl):S222. [CFGD Register: DT11a]
109. Shah PL, Scott SF, Geddes DM, Conway S, Watson A, Nazir T, et al. An evaluation of two aerosol delivery systems for rhDNase. European Respiratory Journal 1997;10(6):1261-6. [CFGD Register: DT11b]
110. ten Berge M, van der Wiel E, Tiddens HAWM, Merkus PJFM, Hop WCJ, de Jongste JC. DNase in stable cystic fibrosis infants: a pilot study. Journal of Cystic Fibrosis 2003;2(4):183-8.
111. van der Giessen L. Does the timing of inhaled dornase alfa matter?. Journal of Cystic Fibrosis 2009;8(Suppl 1):S6-9. [CFGD Register: BD116a]
112. van der Giessen LJ, Gosselink R, de Jongste JC, Hop WCJ, Tiddens HAWM. Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis [abstract]. Journal of Cystic Fibrosis 2005;4 Suppl:S97. [CFGD Register: BD116b]
113. van der Giessen LJ, de Jongste JC, Gosselink R, Hop WC, Tiddens HA. RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology 2007;42(7):624-30. [CFGD Register: BD116b]
114. Weck MB, Retsch-Bogart GZ, Scott CS. Efficacy of DNase in individual children using the N-of-1 study design [abstract]. Pediatric Pulmonology 1999;Suppl 19:285.
115. Wilson CJ, Robbins LJ, Murphy JM, Chang AB. Is a longer time interval between recombinant human deoxyribonuclease (dornase alfa) and chest physiotherapy better? A multi-center, randomized crossover trial. Pediatric Pulmonology 2007;42(12):1110-6.
116. Cho, Eva Cost of medications [personal communication]. Email to: C Yang 15 April 2015.
117. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
118. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Willey-Courand DB, et al. Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health. American Journal of Respiratory and Critical Care Medicine 2007;176(10):957-69.
119. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
120. Higgins JPT, Altman DG on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
121. Jaques A, Daviskas E, Turton JA, McKay K, Cooper P, Stirling RG, et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008;133(6):1388-96.
122. Jones AP, Riley RD, Williamson PR, Whitehead A. Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials. Clinical Trials 2009;6(1):16-27.
123. Lierberman J. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. Journal of the American Medical Association 1968;205:312-3.
124. Menzin J, Oster G, Davies L, Drummond MF, Greiner W, Lucioni C, et al. A multi national economic evaluation of rhDNase in the treatment of cystic fibrosis. International Journal of Technology Assessment in Healthcare 1996;12(1):52-61.
125. National Institute for Health and Clinical Excellence. Mannitol dry powder for inhalation for treating cystic fibrosis. www.nice.org.uk/guidance/ta266/documents/cystic-fibrosis-mannitol-final-appraisal-determinaton3 Oct 2012:1-62.
126. Oster G, Huse D, Lacey MJ, Regan MM, Fuchs HJ. Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis. Annals of Pharmacotherapy 1995;29(5):459-64.
127. Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. Journal of Cystic Fibrosis 2009;8(2):91-6.
128. Sly P, Brennan S, Gangell C, de Klerk N, Murray C, Mott L, et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. American Journal of Respiratory and Critical Care Medicine 2009;180(2):146-52.
129. von der Schulenburg JMG, Greiner W, von der Hardt H. Socioeconomic evaluation of the influence of rhDNase on the costs of treating respiratory tract infections in patients with cystic fibrosis [Soziookonomische Evaluation des Einflusses von rhDNase auf die Kosten der Behandlung von Infektionen der Atemwege bei Patienten mit zystischer Fibrose]. Medizinische Klinik 1995;90(4):220-4.
130. Wark P, McDonald V. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD001506.pub3]
131. Jones AP, Wallis CE, Kearney CE. Recombinant human deoxyribonuclease for cystic fibrosis. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD001127]
132. Jones AP, Wallis C. Dornase alfa for cystic fibrosis. Cochrane Database of Systematic Reviews 2010, Issue 3. [DOI: 10.1002/14651858.CD001127]
133. Kearney CE, Wallis CE. Deoxyribonuclease for cystic fibrosis. Cochrane Database of Systematic Reviews 1998, Issue 4. [DOI: 10.1002/14651858.CD001127]